Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Senti Biosciences Holdings, Inc. Common Stock

SNTI

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Last trade $0.1006
Day change -$0.0354 (-26.03%)
Day range $0.0961 – $0.14
Volume 525,883
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.38M
Price / earnings
—
Price / book
-1.58×
Price / sales
97.89×
EV / sales
52.98×
EV / EBITDA
-0.05×

Profitability

Earnings per share
-$1.29
Return on assets
-149.72%
Return on equity
1,457.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.17×
Current ratio
0.83×
Quick ratio
0.83×
Cash ratio
0.41×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$38.05M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SNTI, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$17K$16K$22K$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$17K$16K$22K$0$0$0$0$0
Selling, general and administrative$6.74M$6.23M$5.85M$6.43M$6.77M$7.12M$8.08M$6.56M
Research and development$7.77M$5.28M$7.76M$10.52M$10.03M$9.28M$7.77M$8.66M
Total operating expenses$14.51M$4.63M$18.66M$16.95M$16.8M$16.4M$16.17M$15.22M
Operating income-$14.49M-$4.62M-$18.64M-$16.95M-$16.8M-$16.4M-$16.17M-$15.22M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$12.75M-$4.22M-$14.47M-$18.13M-$14.73M-$14.11M-$610K-$28.87M
Income taxes$0$0$0$0$0$0$0$0
Net income-$12.75M-$4.22M-$14.47M-$18.13M-$14.73M-$14.11M-$610K-$28.87M
Net income attributable to common shareholders-$12.75M-$4.22M-$14.47M-$18.13M-$14.73M-$14.11M-$3.13M-$28.87M
EBITDA-$13.82M-$10.81M-$12.69M-$16.04M-$15.88M-$15.47M-$14.92M-$14.27M
Basic earnings per share-$0.41-$0.14-$0.52-$0.69-$0.56-$1.41-$0.67-$6.31
Diluted earnings per share-$0.41-$0.14-$0.52-$0.69-$0.56-$1.41-$0.67-$6.31

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Senti Bio to Present at the Citizens JMP Life Sciences Conference

Senti Biosciences, a clinical-stage biotechnology company, announced that it will present positive preliminary clinical results of its lead program SENTI-202 in the treatment of patients with Relapsed/Refractory AML on May 8, 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 18, 20241-for-10reverse split
Oct 21, 20131-for-100reverse split
Apr 11, 20061-for-1,000reverse split